Homepage
Author:
Solid Biosciences Inc.
Posted Date:
May 7, 2026
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences Inc.
May 7, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc.
May 3, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences Inc.
May 3, 2026
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences Inc.
May 3, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc.
April 30, 2026
1
2
3
Next
